Neoantigen × AI
Daily research signal
№54Brief

NEJM Editorial: Intismeran Succeeds Where ICI Intensification Failed

One item today, but a meaningful one: a NEJM editorial accompanying a successful Phase 3 trial of the personalized cancer vaccine Intismeran in adjuvant melanoma — a setting where, per the author, ICI intensification has repeatedly failed.Oncodaily

The sector-relevant details are the kinetics (curves separate only after ~6 months, consistent with delayed vaccine-induced immunity) and the mechanistic case for pairing vaccines, which generate new T cell responses, with checkpoint inhibitors that reinvigorate existing ones.Oncodaily The editorial also sketches the field's next act: shared-hotspot vaccines for cancer interception, a step beyond fully personalized constructs.Oncodaily

1new story
ClinicalyesterdayNew

Mark Yarchoan Discusses Personalized Cancer Vaccines in Melanoma Treatment and Prevention - Oncodaily

Mark Yarchoan, co-founder and CSO of Adventris Pharmaceuticals, published a NEJM editorial accompanying the Phase 3 trial of the personalized cancer vaccine Intismeran in adjuvant melanoma, calling the results vindication for a field long marked by clinical failures. He highlights that the curves separate only after ~6 months — consistent with delayed onset of vaccine-induced immunity — and argues Intismeran succeeded where ICI intensification repeatedly failed, since vaccines stimulate new T cell responses while ICIs invigorate existing ones. For investors, the readout supports the vaccine-plus-ICI combination logic in adjuvant settings and, by extension, the neoantigen-prediction pipelines that underpin personalized constructs. Yarchoan also flags the prevention opportunity: a shared vaccine against 25 recurrent mutational hotspots in KRAS, BRAF, and PIK3CA could in theory target mutations found in more than 70% of colorectal, pancreatic, uterine, and melanoma cases.

news · yesterday · Oncodaily